香港管家婆资料免费大全

Intranasal COVID-19 vaccine headed to clinical trials

Biao He in lab with student
The new vaccine is based on a viral delivery platform developed by He containing modified strains of parainfluenza virus 5, which causes kennel cough in dogs but is harmless to humans. (Photo by Andrew Davis Tucker)

香港管家婆资料免费大全-based startup聽聽received federal funding to support a comparative Phase 2b clinical trial of CVXGA, the company鈥檚 intranasal vaccine candidates designed to protect against COVID-19.

As part of the award from Project NextGen, a federal initiative based in the U.S. Department of Health and Human Services (HHS), CyanVac will sponsor a randomized, double-blind Phase 2b study with 10,000 participants to compare the efficacy and safety of the intranasal vaccine against an FDA-approved mRNA-based COVID-19 vaccine.

The new vaccine is based on a viral delivery platform developed by He containing modified strains of parainfluenza virus 5, which causes kennel cough in dogs but is harmless to humans.

Biao He (Photo by Andrew Davis Tucker)

CyanVac is a聽聽(GRA)-funded startup, founded by Biao He, GRA Distinguished Investigator, Fred C. Davidson Distinguished University Chair in Veterinary Medicine and a faculty member in UGA鈥檚聽聽(CVM). He served on a White House panel to advise on the future of COVID-19 vaccines and was named both UGA Inventor and Entrepreneur of the Year.

鈥淲e are very excited about this opportunity to test a novel intranasal COVID vaccine whose technology platform has been developed at UGA,鈥 said He, who is based in UGA鈥檚 Department of Infectious Diseases. 鈥淭he name of our vaccine鈥擟VXGA鈥攊s a tribute to UGA and CVM whose support over the years made this possible.鈥

鈥檚 goal is to advance new, innovative vaccines and therapeutics that provide longer lasting and more durable protection against COVID-19. The award is one of the first made through the聽, a consortium funded by the HHS聽聽(BARDA) to accelerate product and technology development.

The Phase 2b study, which will begin this fall, will be carried out by BARDA鈥檚 Clinical Studies Network, focusing on evaluating the vaccine in a subset of participants who are at a higher risk of severe disease.